Holen Sie sich die Stockscreener-App
8.50
3.48%
0.30
Handel nachbörslich:
8.50
Schlusskurs vom Vortag:
$8.20
Offen:
$8.13
24-Stunden-Volumen:
818.85K
Relative Volume:
1.20
Marktkapitalisierung:
$459.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-3.001
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
+1.74%
1M Leistung:
+63.80%
6M Leistung:
+296.50%
1J Leistung:
+6.60%
1-Tages-Spanne:
$7.90
$8.66
1-Wochen-Bereich:
$7.75
$8.66
52-Wochen-Spanne:
$1.45
$11.72
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
8.50 | 442.81M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
What makes Lexeo Therapeutics Inc. stock attractive to growth fundsQuarterly Market Summary & Real-Time Volume Analysis Alerts - newser.com
How to monitor Lexeo Therapeutics Inc. with trend dashboardsWeekly Trend Report & AI Based Trade Execution Alerts - newser.com
Using flow based indicators on Lexeo Therapeutics Inc.Weekly Investment Report & Verified Entry Point Signals - newser.com
Will Lexeo Therapeutics Inc. stock outperform Nasdaq index2025 Technical Overview & Technical Pattern Based Signals - newser.com
Using data filters to optimize entry into Lexeo Therapeutics Inc.Dip Buying & Free Fast Gain Swing Trade Alerts - newser.com
Can Lexeo Therapeutics Inc. stock double in next 5 yearsPortfolio Gains Report & Daily Technical Forecast Reports - newser.com
Why hedge funds are buying Lexeo Therapeutics Inc. stock2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
Is Lexeo Therapeutics Inc a good long term investmentGlobal Market Influence & Free Hedging Tactics for Volatile Markets - earlytimes.in
Best data tools to analyze Lexeo Therapeutics Inc. stockInsider Selling & AI Enhanced Trading Alerts - newser.com
Leerink Partnrs Issues Positive Forecast for LXEO Earnings - Defense World
Lexeo Therapeutics, Inc.: A Deep Dive (NASDAQ:LXEO) - Seeking Alpha
Smart tools for monitoring Lexeo Therapeutics Inc.’s price action2025 Pullback Review & Daily Stock Trend Reports - newser.com
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease - streetwisereports.com
Analyzing recovery setups for Lexeo Therapeutics Inc. investorsJobs Report & Verified Chart Pattern Signals - newser.com
Biotech Firm Uncovers Breakthrough Gene Therapy in New York - streetwisereports.com
How to integrate Lexeo Therapeutics Inc. into portfolio analysis toolsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com
Is a relief rally coming for Lexeo Therapeutics Inc. holdersWeekly Profit Summary & Free Weekly Watchlist of Top Performers - newser.com
Lexeo Therapeutics Announces Progress in FDA Discussions and Positive Interim Data for LX2006 - TradingView
Is Lexeo Therapeutics Inc. a candidate for recovery playBond Market & Free Community Consensus Stock Picks - newser.com
Why Lexeo Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Reactions & Community Supported Trade Ideas - newser.com
Therapeutics Company Advances Gene Therapy Breakthrough - streetwisereports.com
Lexeo Therapeutics reports on LX2006 approval pathway - MSN
Chardan Raises Price Target on Lexeo Therapeutics to $17 From $15, Keeps Buy Rating - MarketScreener
HC Wainwright & Co. Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Leerink Partners Issues Positive Forecast for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In - Stocktwits
Chardan Capital Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO) - Seeking Alpha
Lexeo, FDA position Friedreich ataxia therapy for accelerated path - BioWorld MedTech
Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target - TipRanks
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - Stocktwits
Lexeo says FDA open to speedier approval of rare disease gene therapy - BioPharma Dive
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment - MarketScreener
Lexeo up after regulatory update on ataxia drug (LXEO:NASDAQ) - Seeking Alpha
Lexeo’s gene therapy for Friedreich ataxia shows promising results By Investing.com - Investing.com Canada
Lexeo Therapeutics Advances FDA Discussions for LX2006 - TipRanks
Lexeo Therapeutics announces progress in FDA discussions for LX006 in Friedreich ataxia cardiomyopathy - MarketScreener
Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway for LX2006 in Friedreich Ataxia with Promising Interim Data - Quiver Quantitative
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - The Manila Times
Lexeo Therapeutics Announces Progress In FDA Discussions For LX006 In Friedreich Ataxia Cardiomyopathy - TradingView
Lexeo Therapeutics Announces Progress in FDA Discussions - GlobeNewswire
23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan
Can a trend reversal in Lexeo Therapeutics Inc. lead to recoveryJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Is Lexeo Therapeutics Inc. stock a top momentum playRate Hike & Daily Growth Stock Investment Tips - newser.com
Can Lexeo Therapeutics Inc. recover in the next quarterDip Buying & Verified Swing Trading Watchlist - newser.com
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Robertson Jenny | Chief Legal Officer |
Aug 18 '25 |
Sale |
4.67 |
542 |
2,530 |
62,556 |
| Adler Eric | Chief Medical Officer |
Aug 18 '25 |
Sale |
4.67 |
608 |
2,838 |
67,073 |
| Townsend Richard Nolan | Chief Executive Officer |
Aug 18 '25 |
Sale |
4.67 |
2,735 |
12,767 |
220,058 |
| See Tai Sandi | Chief Development Officer |
Aug 18 '25 |
Sale |
4.67 |
382 |
1,783 |
58,860 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):